​

Bicara Therapeutics Stock (NASDAQ:BCAX)

ForecastOwnershipFinancialsChart
Bicara Therapeutics by TradingView

Previous Close

$20.06

52W Range

$7.80 - $20.25

50D Avg

$16.71

200D Avg

$14.24

Market Cap

$1.09B

Avg Vol (3M)

$537.64K

Beta

-0.77

Div Yield

-

BCAX Company Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

55

IPO Date

Sep 13, 2024

Website

BCAX Performance

BCAX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-82.39M$-39.89M$-37.66M
Net Income$-68.00M$-51.98M$-37.84M
EBITDA$-82.39M$-51.96M$-37.72M
Basic EPS$-0.40$-1.00$-0.73
Diluted EPS$-0.40$-1.00$-0.73

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
TNGXTango Therapeutics, Inc.
EYPTEyePoint Pharmaceuticals, Inc.
SEPNSepterna, Inc.
KURAKura Oncology, Inc.
FTREFortrea Holdings Inc.
PRMEPrime Medicine, Inc.
MRVIMaravai LifeSciences Holdings, Inc.
PROKProKidney Corp.
SVRASavara Inc.
PHATPhathom Pharmaceuticals, Inc.